Pharmacokinetics and safety of JTP-4819, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers

Keyphrases

• Pharmacokinetics 100%
• Multiple Dose 100%
• Healthy Male Volunteers 100%
• Orally Active 100%
• Prolyl Oligopeptidase Inhibitor 100%
• Placebo 66%
• Urinary Continence Recovery 66%
• Pharmacokinetic Profile 66%
• Cholinesterase Activity 66%
• Cmax 66%
• Blood Pressure 33%
• Healthy Volunteers 33%
• Blood Biochemistry 33%
• Food Intake 33%
• Safety Assessment 33%
• Clinical Application 33%
• Serious Adverse Events 33%
• Urinalysis 33%
• Body Temperature 33%
• Heart Rate 33%
• Safety Profile 33%
• Pharmacodynamics 33%
• Healthy Young 33%
• Liquid Chromatography-electrospray Ionization-mass Spectrometry (LC-ESI-MS) 33%
• Male Volunteers 33%
• Food Effect 33%
• Mass Spectrometry Methods 33%
• Hematology 33%
• Accumulation Trend 33%
• Plasma Cholinesterase 33%
• Fasted State 33%
• Drug Accumulation 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Pharmacokinetics 100%
• Prolyl Endopeptidase Inhibitor 100%
• Placebo 50%
• Cholinesterase 50%
• Symptom 25%
• Normal Human 25%
• Adverse Event 25%
• Bioavailability 25%
• Pharmacodynamics 25%
• Electrospray Ionization 25%